MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of “Hold” from Analysts

MiNK Therapeutics, Inc. (NASDAQ:INKT) has been given an average recommendation of “Hold” by the five analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $35.00.

A number of research analysts have recently commented on the stock. Wall Street Zen raised shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings raised shares of MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of MiNK Therapeutics in a report on Monday, May 18th.

MiNK Therapeutics Price Performance

INKT opened at $12.20 on Monday. The stock has a market capitalization of $60.76 million, a price-to-earnings ratio of -4.30 and a beta of 0.47. MiNK Therapeutics has a twelve month low of $6.80 and a twelve month high of $76.00. The company has a 50-day simple moving average of $11.09 and a 200 day simple moving average of $11.41.

MiNK Therapeutics (NASDAQ:INKT) last posted its earnings results on Friday, May 15th. The company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.20. Sell-side analysts anticipate that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC acquired a new stake in MiNK Therapeutics, Inc. (NASDAQ:INKT) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned about 0.55% of MiNK Therapeutics at the end of the most recent reporting period. 2.87% of the stock is currently owned by institutional investors and hedge funds.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.